Proteomics Market to Reach $94.7 Billion by 2035 at 10.0% CAGR | Thermo Fisher Scientific, Bruker, Illumina Among Key Players

The global proteomics market, valued at USD 35.7 billion in 2025, will climb to USD 40.2 billion in 2026 and is on course to reach USD 94.7 billion by 2035, expanding at a compound annual growth rate of 10.0% over the 2026 to 2035 forecast period. That trajectory reflects intensifying demand across pharmaceutical drug development, clinical diagnostics, and personalized medicine, three sectors that now depend on protein-level biological intelligence that genomics alone cannot supply. For investors, biopharma strategists, and technology vendors assessing their next decade of positioning, this market represents one of the more durable growth opportunities in the life sciences sector.

To explore the complete findings, request a free sample of the report at https://www.rootsanalysis.com/reports/proteomics-market/request-sample.html

MARKET OVERVIEW: From Genome to Proteome
Proteomics is the systematic, large-scale analysis of all proteins expressed within a cell, tissue, or organism at a given time. Where genomics tells researchers what instructions the body carries, proteomics reveals what those instructions are actually producing, and how those proteins interact, malfunction, or change in disease states. That distinction has direct commercial and clinical value. Proteins are the primary targets for most approved drugs; identifying which proteins go awry in conditions such as Alzheimer's disease, cancer, and multiple sclerosis creates a direct pathway to both biomarker discovery and drug candidate development.

The market's current momentum traces back to rapid advances in mass spectrometry, which remains the gold standard analytical tool in proteomics, and to the integration of artificial intelligence and machine learning into data analysis pipelines. AI-enabled bioinformatics now accelerates biomarker identification, improves predictive modeling for disease progression, and compresses the timeline from discovery to translational research. These computational capabilities work in concert with hardware improvements: the introduction of fourth-generation (4D) proteomics mass spectrometers and next-generation protein microarrays has materially improved throughput, sensitivity, and resolution across the workflow.

Corporate activity underscores how strategically significant this field has become. In January 2026, Illumina announced its acquisition of SomaLogic to strengthen customer access to multiomics capabilities, following its earlier announcement of that deal in June 2025. In October 2025, Thermo Fisher Scientific entered a strategic collaboration with AstraZeneca BioventureHub to advance R&D in proteomics, molecular genomics, and chromatography. And in February 2026, Nautilus Biotechnology launched its Voyager Platform, designed to map up to 10 billion intact proteins and proteoforms simultaneously in a single run. These are not incremental product updates; they are infrastructure commitments that signal where the industry's center of gravity is moving.

KEY GROWTH DRIVERS
Technological advancement in mass spectrometry and bioinformatics. Mass spectrometers capable of 4D proteomics analysis and AI-driven computational tools are making protein analysis faster, more accurate, and more accessible to biopharma organizations. As these platforms improve, adoption expands beyond specialist research labs and into routine clinical workflows. The US FDA is expected to approve more than 10 novel personalized therapeutic modalities annually through 2026, each requiring the kind of protein-level data that advanced spectrometry provides.

Rising demand for personalized and precision medicine. Pharmaceutical companies are under growing pressure to develop therapies that target specific patient subpopulations. Proteomics is a central tool in that effort, enabling drug developers to identify precise protein biomarkers that stratify patients, predict treatment response, and monitor outcomes. Therapy developers are actively evaluating proteomics platforms for integration into preclinical and clinical drug development workflows.

Government and private funding for proteomics infrastructure. Substantial investment from governments and private organizations is flowing into proteomics research capabilities and infrastructure, particularly in North America and Asia-Pacific. This funding accelerates instrument adoption, builds talent pipelines, and expands the base of institutions capable of conducting high-quality proteomics research.

Emergence of single-cell and spatial proteomics. Researchers are applying single-cell proteomics and spatial proteomics techniques to decode cellular heterogeneity, a dimension of biology that bulk-sample methods cannot capture. These approaches are enabling more granular understanding of tumor microenvironments, immune cell behavior, and disease mechanisms, opening new diagnostic and therapeutic categories.

Multi-omics integration. The convergence of proteomics with genomics, transcriptomics, and metabolomics is creating a more complete picture of disease biology. Illumina's recent deployment of its Connected Multiomics platform, which combines spatial transcriptomics, proteomics, and epigenomics for oncology applications, illustrates how multi-omics integration is moving from research concept to commercial product.

MARKET SEGMENTATION: Kits, Reagents, and Spectrometry Lead
The proteomics market segments across type of offering, technology, application area, end user, and geography. By offering type, kits and reagents capture the largest share at approximately 75% of the total market. Their dominance reflects a structural dynamic: consumables require continuous replenishment, generating a recurring revenue base that instruments and one-time service contracts cannot replicate. Within this category, spectrometry reagents command nearly 90% of the kits and reagents segment, a reflection of how thoroughly mass spectrometry has become embedded in standard proteomics workflows.

Among instrument and technology types, the spectrometry segment holds close to 30% of the global market. Core proteomics services, covering protein identification, quantification, and characterization, account for more than 60% of the proteomics services segment, driven by the need for specialized high-cost equipment that most research organizations prefer to outsource. By end user, pharmaceutical and biotechnology companies are the dominant buyers, given their intensive use of proteomics platforms for biomarker identification and drug candidate advancement. The research application area leads by share; however, the diagnostics segment is gaining ground as protein-based biomarkers become standard in clinical testing.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/proteomics-market/request-quote.html

REGIONAL INSIGHTS: North America Leads, Asia-Pacific Accelerates
North America holds more than 40% of global proteomics market share, a position it will maintain through 2035 at a CAGR of 9.8%. The region's leadership stems from its concentration of world-class research universities, a dense biopharma industry base, and the technical infrastructure required to support high-throughput proteomics workflows. The United States, in particular, drives investment in next-generation instruments and the AI-based bioinformatics platforms that process their output.

Asia-Pacific is the fastest-growing region, with a projected CAGR of 11.7% through 2035, outpacing the global average. Expanding pharmaceutical manufacturing capacity, increasing government investment in life sciences research, and growing clinical research activity across China, India, Japan, and South Korea are together driving accelerated instrument adoption and services demand across the region. Europe maintains a strong presence in academic and translational research proteomics, supported by publicly funded research programs across Germany, the UK, and France.

COMPETITIVE LANDSCAPE
The proteomics market features more than 100 solution providers, spanning large diversified life sciences companies, specialist proteomics firms, and emerging technology startups. Key players profiled in Roots Analysis's report include Agilent Technologies, Allele Life Sciences, Bertis, BGI Genomics, Bio-Rad Laboratories, Bruker, CellCarta, Creative Biolabs, Creative Proteomics, Cytiva, Macrogen, Merck, Nautilus Biotechnology, Olink, PerkinElmer, Promega, Promise Proteomics, Proteome Factory, Proteome Sciences, Proteomics International, SCIEX, Seer, SomaLogic, Thermo Fisher Scientific, and VProteomics.

The competitive dynamic is active and multi-directional. Established players such as Thermo Fisher Scientific and Illumina are moving to consolidate capabilities through acquisitions and strategic collaborations, while startups such as Nautilus Biotechnology and Seer are competing on platform innovation, specifically by offering new protein mapping architectures that challenge the mass spectrometry incumbency. The primary battleground sits at the intersection of throughput, sensitivity, and data integration, with the companies that can offer complete, AI-enabled workflows from sample prep through clinical interpretation positioned most favorably.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/proteomics-market.html

Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.